BusinessTESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder CancerBy Nasdaq OMXFeb 26, 2018, 8:00 PM UTC
BusinessTESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in GermanyBy Nasdaq OMXDec 15, 2017, 9:00 AM UTC
BusinessTESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian CancerBy Nasdaq OMXNov 20, 2017, 12:01 PM UTC
BusinessTesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the YearBy Nasdaq OMXApr 7, 2017, 12:30 PM UTC
BusinessTESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast CancerBy Nasdaq OMXMar 27, 2017, 7:45 PM UTC
BusinessTesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGOBy Nasdaq OMXMar 13, 2017, 3:10 PM UTC
